Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Crinetics Pharmaceuticals Inc (NQ: CRNX ) 53.06 +0.36 (+0.68%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Crinetics Pharmaceuticals Inc < Previous 1 2 Next > Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 07, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment October 11, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END Via FinancialNewsMedia Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Near the Top of Equities by Percentage Gain on 9/11 September 11, 2023 Via Investor Brand Network Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023 September 20, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock September 12, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock September 11, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly September 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 08, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023 June 21, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics to Highlight Broad Pipeline at ENDO 2023 June 09, 2023 Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update May 04, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update February 28, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference February 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference January 09, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 12, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Provides Update on CRN04777 Program November 28, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference November 22, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 10, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly October 13, 2022 Topline results for PATHFNDR-1 study expected in Q3 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism October 06, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer October 03, 2022 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.